Monitor early U.S. commercial uptake of MYQORZO and topline results from the ACACIA-HCM trial in Q2 2026, which could validate expansion into non-obstructive HCM. The high cash balance supports operations, but the significant increase in operating expenses raises questions about profitability timeline.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $62.89entry
- T+1 · 9mo ago −0.41%α +0.13% · $62.63
- T+5 · 9mo ago −0.99%α +0.11% · $62.27
- T+20 · 8mo ago −0.80%α +4.44% · $62.39
- T+60 · 6mo ago +25.25%α +18.30% · $78.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cytokinetics reported its transition to a commercial-stage company following FDA, China, and EU approvals of MYQORZO for obstructive HCM, with the U.S. launch underway. The company posted a wider net loss of $785M in 2025 due to increased R&D and commercial readiness spending, while maintaining ~$1.22B in cash. It provided 2026 guidance with $830M–$870M in combined R&D and SG&A expenses.
Key Financial Metrics
Key Facts
- MYQORZO approved in U.S., China, and EU for symptomatic obstructive HCM; U.S. launch began in January 2026 with first prescriptions dispensed.
- Total 2025 revenue was $88.0M (up from $18.5M in 2024), driven by a $52.4M technology transfer payment to Bayer and $15.0M in milestone revenue from MYQORZO approvals.
- 2025 net loss was $785.0M (vs. $589.5M in 2024); Q4 2025 net loss was $183.0M (vs. $150.0M in Q4 2024), reflecting higher R&D and G&A expenses for commercialization.
- Cash, cash equivalents, and investments were $1.22B as of December 31, 2025, down from $1.25B in Q3; excluding a $100M loan draw, cash declined by $134M in Q4.
- 2026 guidance: GAAP combined R&D and SG&A expenses of $830M–$870M, including $120M–$130M in non-cash stock-based compensation.
Financial Impact
Revenue increased 376% YoY to $88.0M in 2025, but net loss widened by $195.5M due to $76.6M higher R&D and $69.0M higher G&A expenses. Cash burn (excluding financing) was $134M in Q4 2025.
Segment Breakdown
| Segment | Revenue |
|---|---|
| aficamten | $15.0M |
| technology transfer | $52.4M |
Risk Factors
- High cash burn rate ($134M in Q4 excluding financing) could pressure the balance sheet if product revenue does not scale quickly.
- Future profitability depends on MYQORZO's commercial success and additional regulatory approvals, which are not guaranteed.
- Increased G&A spend ($284.3M in 2025) reflects sales force buildout, creating fixed costs that require strong revenue growth to offset.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-067012 |
| Document: cytk-20260224.htm | 0001193125-26-067012 |
| Document: 0001193125-26-067012-index-headers.html | 0001193125-26-067012 |
| Document: 0001193125-26-067012-index.html | 0001193125-26-067012 |
| Document: 0001193125-26-067012.txt | 0001193125-26-067012 |
| CONTEXT: Previous Earnings (2026-02-24) | 0001193125-26-067012 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers